1. Home
  2. ENIC vs IMVT Comparison

ENIC vs IMVT Comparison

Compare ENIC & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Enel Chile S.A. (Each representing 50 shares of)

ENIC

Enel Chile S.A. (Each representing 50 shares of)

N/A

Current Price

$4.19

Market Cap

6.3B

Sector

Utilities

ML Signal

N/A

Logo Immunovant Inc.

IMVT

Immunovant Inc.

N/A

Current Price

$34.23

Market Cap

6.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ENIC
IMVT
Founded
2016
2018
Country
Chile
United States
Employees
N/A
N/A
Industry
Electric Utilities: Central
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.3B
6.3B
IPO Year
2015
2019

Fundamental Metrics

Financial Performance
Metric
ENIC
IMVT
Price
$4.19
$34.23
Analyst Decision
Hold
Buy
Analyst Count
5
17
Target Price
$4.94
★ $48.50
AVG Volume (30 Days)
544.7K
★ 1.4M
Earning Date
10-28-2026
11-09-2026
Dividend Yield
★ 4.58%
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$12.31
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$101.18
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.64
$21.86
52 Week High
$4.74
$45.42

Technical Indicators

Market Signals
Indicator
ENIC
IMVT
Relative Strength Index (RSI) 42.01 58.40
Support Level $4.11 $26.01
Resistance Level $4.47 $34.60
Average True Range (ATR) 0.11 1.47
MACD -0.01 0.98
Stochastic Oscillator 20.84 65.41

Price Performance

Historical Comparison
ENIC
IMVT

About ENIC Enel Chile S.A. (Each representing 50 shares of)

Enel Chile SA is an electricity utility company engaged, through its subsidiaries and affiliates, in the generation, transmission, and distribution of electricity across Chile. The Company operates through two main segments: the Generation Business, which includes companies that own and operate power plants supplying electricity to the grid and generates the majority of revenue; and the Distribution and Network Business, which consists of companies operating under public utility concessions to distribute electricity to end customers.

About IMVT Immunovant Inc.

Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.

Share on Social Networks: